SPDYE6: A Potential Drug Target and Biomarker for the Speedy/RINGO Cell Cycle Regulator Family

Target Name: SPDYE6

NCBI ID: G729597

SPDYE6

SPDYE6: A Potential Drug Target and Biomarker for the Speedy/RINGO Cell Cycle Regulator Family

Introduction

The Speedy/RINGO cell cycle regulator family is a growing focus of research in the field of cell biology due to its critical role in regulating the cell cycle and influencing various cellular processes. The SPDYE6 gene, located on chromosome 18q21, is a member of this family and has been shown to play a crucial role in the regulation of the cell cycle.

SPDYE6: Structure and Function

The SPDYE6 gene encodes a protein that belongs to the family of cyclins, which are important regulators of the cell cycle. These proteins help to keep the cell cycle in check, ensuring that cells divide and grow at the appropriate rate and returning to the state of G0. The SPDYE6 protein is composed of 254 amino acid residues and has a calculated molecular mass of 33.4 kDa.

SPDYE6 functions as a negative regulator of the cell cycle, preventing the progression of cells into the G1 phase of the cell cycle when there is an increase in cellular tension or stress. It does this by interacting with and inhibiting the activity of the cyclin D1 protein , which is responsible for regulating the G1 phase of the cell cycle.

SPDYE6 has been shown to play a crucial role in the regulation of cell cycle progression in various organisms, including bacteria, yeast, and animals. For example, studies have shown that SPDYE6 can inhibit the G1 phase of the cell cycle in bacteria and yeast, leading to a delay in cell growth and an increase in the time required to reach the S phase.

SPDYE6 has also been shown to be involved in the regulation of cell division in cancer cells. For instance, studies have shown that SPDYE6 can inhibit the progression of cancer cells into the G1 phase of the cell cycle, leading to a delay in cell growth and an increase in the time required to reach the S phase.

SPDYE6 as a Drug Target

The potential use of SPDYE6 as a drug target is due to its involvement in the regulation of the cell cycle and its ability to inhibit the progression of cells into the G1 phase of the cell cycle. This suggests that SPDYE6 could be an effective target for cancer therapies that aim to inhibit cell division.

SPDYE6 has been shown to interact with various drug targets involved in the cell cycle, including the inhibitor of DNA binding (ID4) and the cyclin D1 protein. These interactions suggest that SPDYE6 could be a drug target that can be inhibited by small molecules, such as drugs used in the treatment of cancer.

SPDYE6 as a Biomarker

SPDYE6 has also been shown to be involved in the regulation of the cell cycle in various organisms, including bacteria, yeast, and animals. This suggests that SPDYE6 could be a valuable biomarker for the diagnosis and prognosis of various diseases.

SPDYE6 has been shown to play a role in the regulation of cell growth and division in various organisms, including bacteria, yeast, and animals. For example, studies have shown that SPDYE6 can inhibit the growth of bacteria and yeast cells under stress, suggesting that it may be a useful biomarker for the treatment of bacterial and yeast infections.

SPDYE6 has also been shown to play a role in the regulation of cell cycle progression in cancer cells. For instance, studies have shown that SPDYE6 can inhibit the progression of cancer cells into the G1 phase of the cell cycle, leading to a delay in cell growth and an increase in the time required to reach the S phase. This suggests that SPD

Protein Name: Speedy/RINGO Cell Cycle Regulator Family Member E6

The "SPDYE6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPDYE6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets